Системы оценки, используемые при внебольничной пневмонии: возможности и ограничения


DOI: https://dx.doi.org/10.18565/pharmateca.2018.8.44-48

О.В. Фесенко, А.И. Синопальников

Российская медицинская академия непрерывного профессионального образования, Москва, Россия
Тяжелая пневмония ассоциируется с высокой летальностью, поэтому своевременная и правильная оценка степени тяжести играет важную роль при ведении таких пациентов. В статье представлены анализ современных рекомендаций по ведению больных тяжелой внебольничной пневмонией, преимущества и недостатки шкал для оценки риска неблагоприятного исхода при пневмонии.
Ключевые слова: внебольничная пневмония, шкалы оценки степени тяжести, риск неблагоприятного исхода

Литература


1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–210. Doi: 10.1016/S0140-6736(17)32152-9.

2. Prina E., Ranzani O.T., Torres A. Community-acquired pneumonia. Lancet 2015;386:1097–108. Doi: 10.1016/S0140-6736(15)60733-4.

3. Fine M.J., Smith D.N., Singer D.E. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am. J. Med. 1990;89:713–21.

4. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997;336:243–50. Doi: 10.1056/NEJM199701233360402.

5. Woodhead M., Welch C.A., Harrison D.A., et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit. Care. 2006;10(Suppl. 2):S1. Doi: 10.1186/cc4927.

6. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.

7. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007;44(Suppl. 2):27–72. Doi: 10.1086/511159.

8. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin. Infect. Dis. 2008;47:375–84.

9. Espana P.P., Capelastegui A., Gorordo I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am. J. Respir. Crit .Care Med. 2006;174:1249–56. Doi: 10.1164/rccm.200602-177OC.

10. Singer M., Deutschman C.S., Seymour C.W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10. Doi: 10.1001/jama.2016.0287.

11. Marti C., Garin N., Grosgurin O., et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit. Care. 2012;16:R141.

12. Chalmers J.D., Mandal P., Singanayagam A., et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37:1409–20.

13. Ranzani O.T., Prina E., Menendez R., et al. New sepsis definition (Sepsis-3) and community-acquired pneumonia mortality. A validation and clinical decisionmaking study. Am. J. Respir. Crit. Care Med. 2017;196:1287–97. Doi: 10.1164/rccm.201611-2262.

14. Mortensen E.M., Coley C.M., Singer D.E., et al. Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcomes research team cohort study. Arch. Intern. Med. 2002;162:1059–64.

15. Genne D., Sommer R., Kaiser L., et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 2006;25:159–66.

16. Waterer G. Severity scores and community-acquired pneumonia. time to move forward. Am. J. Respir. Crit. Care Med. 2017;196:1236–38.

17. Lim W.S., Baudouin S.V., George R.C., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl. 3):1–55.

18. Antibiotic Expert Groups. Therapeutic guidelines: antibiotic. Version 14. Melbourne: Therapeutic Guidelines Limited. 2014.

19. Cilloniz C., Ewig S., Polverino E., et al. Microbial aetiology of communityacquired pneumonia and its relation to severity. Thorax. 2011;66:340–46.

20. Roson B., Carratala J., Dorca J., et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin. Infect. Dis. 2001;33:158–65. Doi: 10.1086/321808.

21. Stralin K., Olcen P., Tornqvist E., Holmberg H. Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores. Scand. J. Infect. Dis. 2010;42:426–34.

22. Capelastegui A., Espana P.P., Bilbao A., et al. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC. Infect. Dis. 2012;12:134. Doi: 10.1186/1471-2334-12-134.

23. Singanayagam A., Chalmers J.D. Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet. Respir. Med. 2013;1:653–62.

24. Singanayagam A., Aliberti S., Cilloniz C., et al. Evaluation of severity scoreguided approaches to macrolide use in community-acquired pneumonia. Eur. Respir. J. 2017;50.

25. Valley T.S., Sjoding M.W., Ryan A.M., et al. Association of intensive care unit admission with mortality among older patients with pneumonia. JAMA. 2015;314:1272–9.

26. Renaud B., Santin A., Coma E., et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit. Care Med. 2009;37:2867–74. Doi: 10.1097/CCM.0b013e3181b02dbb.

27. Restrepo M.I., Mortensen E.M., Rello J., et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010;137:552–57.

28. Molina J.A., Seow E., Heng B.H., et al. Outcomes of direct and indirect medical intensive care unit admissions from the emergency department of an acute care hospital: a retrospective cohort study. BMJ. Open. 2014;4:e005553.

29. Jeon K., Yoo H., Jeong B.H., et al. Functional status and mortality prediction in community-acquired pneumonia. Respirology. 2017;22:1400–406. Doi: 10.1111/resp.13072.

30. Ahn B.K., Lee Y.S., Kim Y.J., et al. Prediction model for mortality in cancer patients with pneumonia: comparison with CURB-65 and PSI. Clin. Respir. J. 2016 25 Sep.

31. Sbiti-Rohr D., Kutz A., Christ-Crain M., et al. The National Early Warning Score (NEWS) for outcome prediction in emergency department patients with community-acquired pneumonia: results from a 6-year prospective cohort study. BMJ. Open. 2016;6:e011021.

32. Ranzani O., Taniguchi L., Torres A. Severity scoring systems for pneumonia: current understanding and next steps. Curr. Opin. Pulm. Med. 2018;24:227–36.

33. Menendez R., Martinez R., Reyes S., et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64:587–91. Doi: 10.1136/thx.2008.105312.

34. Frenzen F.S., Kutschan U., Meiswinkel N., et al. Admission lactate predicts poor prognosis independently of the CRB/CURB-65 scores in community-acquired pneumonia. Clin. Microbiol. Infect. 2018;24(3):306.e1-306.e6.

35. Ranzani O.T., Monteiro M.B., Ferreira E.M., et al. Reclassifying the spectrum of septic patients using lactate: severe sepsis, cryptic shock, vasoplegic shock and dysoxic shock. Rev. Bras. Ter. Intensiva. 2013;25:270–78. Doi: 10.5935/0103-507X.20130047.

36. Bermejo-Martin J.F., Cilloniz C., Mendez R., et al. Lymphopenic community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality. EBioMedicine. 2017;24:231–36. Doi: 10.1016/j.ebiom.2017.09.023.

37. Marrie T.J., Lau C.Y., Wheeler S.L., et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. community-acquired pneumonia intervention trial assessing levofloxacin. JAMA. 2000;283:749–55.

38. Carratala J., Fernandez-Sabe N., Ortega L., et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann. Intern. Med. 2005;142:165–72.

39. Yealy D.M., Auble T.E., Stone R.A., et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann. Intern. Med. 2005;143:881–94.


Об авторах / Для корреспонденции


Автор для связи: О.В. Фесенко – д.м.н., проф. кафедры пульмонологии, Российская медицинская академия непрерывного профессионального образования, Москва, Россия; тел. +7 (499) 728-8-23; e-mail: ofessenko@mail.ru


Бионика Медиа